Mucosal candidiasis is extremely common in immunocompromised patients. However, the prevalence of site-specific infection (i.e., oropharyngeal, vaginal, and esophageal candidiasis) can be quite variable depending on the immune status of the host. While vulvovaginal candidiasis is common in normal healthy women, oropharyngeal and esophageal candidiasis are more frequently encountered under immun...

Abstract Background Oteseconazole (VT-1161) is a novel, investigational oral therapy that currently under FDA review for the treatment of recurrent vulvovaginal candidiasis (RVVC). Susceptibility testing was performed on all viable clinical isolates collected from three Phase 3 studies to determine susceptibility causative pathogens oteseconazole versus current standard care, fluconazole. Metho...

The problem Genital infection with candida species is common in women, 75% of whom will have had at least one episode during their lives. Indeed, there is a 15–20% point prevalence of asymptomatic candida carriage in young, nonpregnant, premenopausal women. While acute episodes of candidal vulvovaginitis usually respond rapidly to treatment, some women suVer frequent recurrences or chronic infe...

BACKGROUND The epidemiology of vulvovaginal candidiasis (VVC) and such recurrent infections (RVVC) has been difficult to study as the majority of episodes of these conditions are self-treated by the women affected. In Sweden, all pharmacies are owned by the state and all prescriptions and over-the-counter (OTC) products, such as antifungals, are registered in a database, which offers unique pos...

background vulvovaginal candidiasis (vvc) is a fungal infection of the vagina and vulva. it is usually caused by candida albicans, however, occasionally other candida species are responsible. the optimal treatment of vvc has not yet been defined. the present study was designed to compare the efficacy and safety of a single oral dose of fluconazole with clotrimazole vaginal cream as the treatmen...